

Bio:

Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, and Vice Chief, Division of Gastroenterology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities. Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, and first prospective study of MRE in patients with biopsy-proven NAFLD, and MOZART Trial being the first trial in NASH with comprehensive MRI and 2D and 3D MRE assessment paired with liver biopsies in NASH. His research is funded by the National Institutes of Health including R01 and U01 grant mechanisms, American Gastroenterology Association, National Science Foundation as well as several investigator initiated research projects funded by the industry. He is the Principal Investigator for adult hepatology for the NIDDK-sponsored NASH Clinical Research Network (2009-19) and serves as the Vice-Chair of the Steatosis and Steatohepatitis, Special Interest Group of the American Association for the Study of Liver Diseases. Dr. Loomba has published more than 140 peer-reviewed manuscripts in his area of expertise. He serves on the Editorial Board of Gastroenterology, Journal of Hepatology, GUT and Nature Reviews in Gastroenterology and Hepatology. He is the Deputy Editor of HEPATOLOGY, the official journal of the AASLD.